Daito Pharmaceutical Co., Ltd. · TSE:4577
Daito Pharmaceutical — FY2026 Earnings Presentation
37 slides from Daito Pharmaceutical's earnings presentation, Jul 15, 2026
Slide 1: FY2026 4Q Earnings Presentation
Fiscal Year Ended May 2026 FY2026 4Q Earnings Presentation July 15, 2026 Daito Pharmaceutical Co., Ltd. Tokyo Stock Exchange Prime Market : 4577 Copyright Daito Pharmaceutical Copyright Daito Co., Ltd. Pharmaceutical Co., Ltd.
Slide 2: Contents
Contents I. Overview of Financial Results for FYE May 2026 p. 3 II. Details of Financial Results for FYE May 2026 p. 6 III. Earnings Forecast for FYE May 2027 p. 15 IV. Progress of Medium-term Management Plan "DTP2027" p. 22 Appendix. Company Overview Copyright Daito Pharmaceutical Co., Ltd. 2
Slide 3: I. Overview of Financial Results for FYE May 2026
I. Overview of Financial Results for FYE May 2026 Copyright Daito Pharmaceutical Co., Ltd. 3
Slide 4: Executive Summary
I. Overview of Financial Results for FYE May 2026 Executive Summary FYE May 2026 Financial Results ◼ Consolidated net sales were 50.65 billion yen, a slight increase year-on-year, and EBITDA was 8.02 billion yen, landing with a significant profit increase. ◼ In addition to the net sales contribution
Slide 5: Financial Highlights
I. Overview of Financial Results for FYE May 2026 Financial Highlights ◼ While sales of APIs were weak, sales of FDF products, particularly Gx products and contract-manufactured prescription drugs, increased, resulting in a slight year-on-year increase ◼ Regarding profits, although SG&A expenses inc
Slide 6: II. Details of Financial Results for FYE May 2026
II. Details of Financial Results for FYE May 2026 Copyright Daito Pharmaceutical Co., Ltd. 6
Slide 7: Income Statement Summary
II. Details of Financial Results for FYE May 2026 Income Statement Summary (Millions of yen, %) FYE May 2025 FYE May 2026 YoY change Amount Amount % Net sales 50,643 50,650 +0.0 Cost of sales 42,005 40,753 (3.0) Gross profit 8,637 9,897 +14.6 SG&A expenses 6,017 6,260 +4.0 Operating profit 2,619 3,6
Slide 8: Sales by Category
II. Details of Financial Results for FYE May 2026 Sales by Category ◼ Regarding APIs, while anti-allergy drug APIs increased, the mainstay hemostatic drug APIs decreased, and the budget was not met, resulting in a YoY decrease of 380 million yen, -1.7% ◼ Regarding FDF products, although external pro
Slide 9: New Product Launches by Category
II. Details of Financial Results for FYE May 2026 New Product Launches by Category FDF products APIs December 2025 June 2026 Therapeutic Therapeutic Product Name Original Name Sales Company Product Name Original Name Adoption Status Category Category Lacosamide Antiepileptic Vimpat Antiplatelet Pras
Slide 10: Analysis of Changes in Operating Profit
II. Details of Financial Results for FYE May 2026 Analysis of Changes in Operating Profit Other costs, etc. 293 3,637 (Millions of yen) Utility expenses 157 R&D cost Impact of 297 inventory valuation 394 Change in net sales, product mix, etc. Depreciation 178 Impact of Personal expenses foreign exch
Slide 11: Balance Sheet Summary
II. Details of Financial Results for FYE May 2026 Balance Sheet Summary ◼ Prioritizing stable supply while focusing on inventory optimization based on capital cost-conscious B/S management, inventories decreased by 1.97 billion yen, or -10.7%. ◼ Continuously promoting the optimization of trade recei
Slide 12: Cash Flows Statement Summary
II. Details of Financial Results for FYE May 2026 Cash Flows Statement Summary ◼ Operating CF saw a significant improvement in operating profit, and in addition, the optimization of trade receivable turnover periods, which had been neglected due to past business practices, and the stabilization of a
Slide 13: Trends in Capital Expenditure and R&D Investment
II. Details of Financial Results for FYE May 2026 Trends in Capital Expenditure and R&D Investment CAPEX in H2 (left axis) Depreciation in H2 (left axis) R&D cost for full year (right axis) (Millions of yen) CAPEX in H1 (left axis) Depreciation in H1 (left axis) (Millions of yen) Capital expenditure
Slide 14: Operation Status of the Tenth FDF Building and Future Plans
II. Details of Financial Results for FYE May 2026 Operation Status of the Tenth FDF Building and Future Plans Operating rate (%) Operation rates of adjacent multi-story warehouse Estimated operation by floor (by construction phase) of Tenth FDF Building 100 100 100 100 Utilities FY 2025/05 FY2026/05
Slide 15: III. Full-year Earnings Forecast for FYE 2027
III. Full-year Earnings Forecast for FYE 2027 Copyright Daito Pharmaceutical Co., Ltd. 15
Slide 16: FYE May 2027 Full-year Earnings Forecast
III. Full-year Earnings Forecast for FYE 2027 FYE May 2027 Full-year Earnings Forecast ◼ While Daito expects the business environment to remain challenging due to factors such as yearly drug price revisions and rising raw material costs, Daito is planning for a significant increase in net sales thro
Slide 17: Difference from KGI Targets in DTP2027
III. Full-year Earnings Forecast for FYE 2027 Difference from KGI Targets in DTP2027 Recent Performance and Revised KGI in DTP2027 (million yen) FYE May 2025 FYE May 2026 FYE May 2027 Revised target Result Revised target Result Initial target Revised target Key Revision Factors 1. Non-application of
Slide 18: Questions at the House of Representatives Budget Committee Regarding Dopacol Combination Tablets
III. Full-year Earnings Forecast for FYE 2027 Questions at the House of Representatives Budget Committee Regarding Dopacol Combination Tablets Dopacol Combination Tablets (Levodopa/Carbidopa Combination Tablets) ◼ Essential for all stages of Parkinson's disease ◼ Core therapeutic drug with a 70% mar
Slide 19: Sales Forecast by Category
III. Full-year Earnings Forecast for FYE 2027 Sales Forecast by Category ◼ For APIs, in-house products will remain strong, and external products will continue to perform well, leading to a total increase of +0.86 billion yen, or +3.9%, for the API category. ◼ For FDF products, although external prod
Slide 20: Analysis of Changes in Operating Profit
III. Full-year Earnings Forecast for FYE 2027 Analysis of Changes in Operating Profit (Millions of yen) Impact of Impact of * * Personal expenses foreign inventory valuation Depreciation Change in net sales, 78 exchange 150 10 product mix, etc. 103 867 R&D cost * 4,000 -627 Utility expenses -112 Oth
Slide 21: Shareholder Return Policy
III. Full-year Earnings Forecast for FYE 2027 Shareholder Return Policy ◼ Repurchase of treasury shares • At the Board of Directors meeting held on July 10, 2026, Daito decided to set up 500,000 shares of treasury stock repurchase facility through off-floor trading (ToSTNeT-3), equivalent to 1.7% of
Slide 22: IV. Progress of Medium-term Management Plan DTP2027
Ⅳ. Progress of Medium-term Management Plan “DTP2027" Copyright Daito Pharmaceutical Co., Ltd. 22
Slide 23: Progress of Medium-term Management Plan DTP2027
Ⅳ. Progress of Medium-term Management Plan "DTP2027" Progress of Medium-term Management Plan "DTP2027" ◼ Progress of the Five Pillars of Daito Business Strategy Business strategy Achievement and current state Progress • The Novel Consortium Initiative for product integration has 9 participating comp
Slide 24: Detail (1): Interim Report on Discussions Toward Realizing The Novel Consortium Initiative
Pillar 1. Streamlining of Existing Businesses Ⅳ. Progress of Medium-term Management Plan "DTP2027" Detail (1)： Interim Report on Discussions Toward Realizing The Novel Consortium Initiative Current Participating Companies in “The Novel Consortium Initiative,” Items Under Discussion, and Indicators R
Slide 25: Detail (2): Progress of Activities Toward Breaking Away from High-Mix Low-Volume Production
Pillar 1. Streamlining of Existing Businesses Ⅳ. Progress of Medium-term Management Plan "DTP2027" Detail (2) ：Progress of Activities Toward Breaking Away from “High-Mix Low-Volume Production" ◼ Following discussions within the Novel Consortium Initiative and other bilateral negotiations, the items
Slide 26: Detail (3): Progress of Activities Toward Breaking Away from High-Mix Low-Volume Production
Pillar 1: Streamlining of Existing Businesses Ⅳ. Progress of Medium-term Management Plan "DTP2027" Detail (3) ：Progress of Activities Toward Breaking Away from “High-Mix Low-Volume Production" ◼ Succeeded the business related to Opalmon🄬tablets and Prostandin🄬ointment from Ono Pharmaceutical Co…
Slide 27: Detail (4): Alliance for Strengthening the Stable Supply System for Generic Drugs
Pillar 1: Streamlining of Existing Businesses Ⅳ. Progress of Medium-term Management Plan "DTP2027" Detail (4) ：Alliance for Strengthening the Stable Supply System for Generic Drugs Conclusion of a Basic Agreement on the Succession of Kyorin Pharmaceutical's Generic Drug Business Overview of Business
Slide 28: Detail (5): Progress in the Development and Approval of Generic Drugs in China
Pillar 2. Strengthening our China Business Ⅳ. Progress of Medium-term Management Plan "DTP2027" Detail (5) ：Progress in the Development and Approval of Generic Drugs in China ◼ Although there were some delays for items scheduled for approval in FY2026, the procedures were completed as planned. ◼ To
Slide 29: Detail (6) Current Status of CDMO Business
Pillar 3: Entering into New Businesses Ⅳ. Progress of Medium-term Management Plan "DTP2027" Detail (6) Current Status of CDMO Business ◼ Promoting the establishment of a business foundation in the rare disease field and the global expansion of value-added FDF products through the advancement of the
Slide 30: Details (7): Progress on Addressing PBR Below 1 and Advancement of Capital Allocation
Pillar 4. Addressing PBR Below 1 and Advancement of Capital Allocation Ⅳ. Progress of Medium-term Management Plan "DTP2027" Details (7) ：Progress on Addressing PBR Below 1 and Advancement of Capital Allocation ◼ To resolve the PBR below 1x at an early stage, Daito is strengthening IR/SR activities a
Slide 31: Detail (8) Investment in Human Capital
Pillar 5. Investment in Human Capital Ⅳ. Progress of Medium-term Management Plan "DTP2027" Detail (8) Investment in Human Capital Top-level wage increase in the region Development of a rewarding work environment (2 consecutive years) ◼ Implemented wage increases exceeding the average for companies i
Slide 32: Appendix. Company Overview
Appendix. Company Overview Copyright Daito Pharmaceutical Co., Ltd. 32
Slide 33: Corporate Profile
Appendix. Company Overview Corporate Profile Company name : Daito Pharmaceutical Co., Ltd. Location of head office : 326 Yokamachi, Toyama City, Toyama Founded : June 1942 Fiscal year-end : End of May Representative : Hiroshi Matsumori, President and CEO Number of employees : 1,085 (not including an
Slide 34: Company Creed, Management Philosophy, and Code of Conduct
Appendix. Company Overview Company Creed, Management Philosophy, and Code of Conduct Company Creed Creation, Morale, and Sincerity Company • Be a person who has ideas and thinks deeply. Creed • Be a person with the ability to take action and spirit. • Be a guardian of the Company. Management Philoso
Slide 35: Company Creed, Management Philosophy, and Code of Conduct
Appendix. Company Overview Company Creed, Management Philosophy, and Code of Conduct Code of Conduct Based on our management philosophy, Daito aims to be a company that can be always the first choice of customers. ⚫ Sincere attitude We will comply with laws and regulations and act fairly and imparti
Slide 36: Corporate History
Appendix. Company Overview Corporate History Daitoa Pharmaceutical Trade Control Company Ltd. established as the Facilities company in charge of controlling export of Toyama-made home medicines 1942 June 1949 Built new office and plant to Southeast Asia * Renamed Daito Pharmaceutical Co., Ltd. (curr
Slide 37: Group Company Relationship Chart
Appendix. Company Overview Group Company Relationship Chart Legend APIs FDF products Daito group company relationship chart 21% stake 70% owned subsidiary Anhui Tingworld Daito Pharmaceutical APIs Sales Pharmaceutical (China) Co., Ltd. Local China 21% stake APIs / intermediates Integrated production